News articles about Bellicum Pharmaceuticals (NASDAQ:BLCM) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bellicum Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.3960569461097 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
Shares of Bellicum Pharmaceuticals stock traded down $0.15 during mid-day trading on Monday, hitting $7.81. The company’s stock had a trading volume of 128,145 shares, compared to its average volume of 919,852. The firm has a market cap of $267.23, a P/E ratio of -2.74 and a beta of 0.44. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $15.55. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.37 and a current ratio of 8.37.
A number of brokerages recently issued reports on BLCM. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Raymond James Financial reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. Zacks Investment Research downgraded Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price (down previously from $12.00) on shares of Bellicum Pharmaceuticals in a report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. Bellicum Pharmaceuticals has an average rating of “Hold” and an average price target of $16.88.
In other news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the stock in a transaction on Friday, January 19th. The stock was sold at an average price of $8.20, for a total value of $7,222,027.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 1,141,822 shares of company stock worth $9,475,583. Company insiders own 18.77% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/03/19/bellicum-pharmaceuticals-blcm-earning-somewhat-favorable-news-coverage-study-finds.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.